Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
High Tech Oral Hygiene BasicBites featured on Good Morning San Diego
March 12, 2015
BasicBites from Ortek Therapeutics was featured on Good Morning San Diego. BasicBites are sugar free, soft chews that can help maintain healthy teeth and support the acid-base (pH) level on tooth surfaces that are already in the normal range.
The core technology of BasicBites was developed by Israel Kleinberg, DDS, PhD, DSc, Distinguished Professor in the Department of Oral Biology and Pathology, and Director of the Division of Translational Oral Biology at Stony Brook University. View the brief video here: http://bit.ly/1GJ8Mth
The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.
The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.
“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”
Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”
The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.
“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.
As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.
[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => redesignation2025
[to_ping] =>
[pinged] =>
[post_modified] => 2025-07-21 14:51:44
[post_modified_gmt] => 2025-07-21 18:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4906
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-26 16:35:20
[post_modified_gmt] => 2025-02-26 21:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4231
[post_author] => 4
[post_date] => 2023-07-10 12:37:00
[post_date_gmt] => 2023-07-10 16:37:00
[post_content] =>
SBU Startup, Lahara Bio, presented in the start-up stadium event at the 2023 BIO International Convention in June.
Christopher Ashdown, a MD/PhD student at Stony Brook University, and Center for Biotechnology Program alumnus presented on behalf of Lahara after securing a spot in the coveted forum by winning multiple pitch competitions from NIH SEED office.
According to Ashdown, “Bio 2023 was an amazing experience, and I was thrilled to be able to share the exciting work that we're doing at Lahara Bio with the greater bioscience community. The CfB was incredibly helpful in preparing the company for this conference and has done an excellent job of helping me develop on a personal/professional level".
In addition to the main stage presentation, Ashdown also presented Lahara Bio at the NIH booth. Lahara Bio was sponsored to attend BIO by the NIH after Ashdown won the national investor pitch competition at the NIH Proof of Concept Network annual meeting this past spring.
Lahara Bio is an early-stage biotechnology company using cell-specific mechanical vibration to non-invasively improve biomanufacturing outcomes. Learn more about the company and the team behind Lahara at laharabio.com.
[post_title] => Lahara Bio Presents at BIO International Convention
[post_excerpt] => Stony Brook Start Up, Lahara Bio, was presented at the 2023 BIO International Convention by Christopher Ashdown, a MD/PhD student at Stony Brook University, and Center for Biotechnology Program alumnus.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lahara-bio-presents-at-bio-international-convention
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-22 11:32:58
[post_modified_gmt] => 2024-08-22 15:32:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4231
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4969
[post_author] => 6
[post_date] => 2026-03-23 14:03:09
[post_date_gmt] => 2026-03-23 18:03:09
[post_content] =>
We have exciting news to share for one of our Cfb clients Biocogent, a research and development biotechnology company that manufactures ingredients used in topical and medical skin care products. The company has recently closed a $10 million deal with Town of Brookhaven Industrial Development Agency (IDA) to establish a three-building campus in North Bellport and invest further in infrastructure and equipment and bring outsourced manufacturing back to Long Island, expanding from their previous 12,000 square foot facility at Stony Brook University's Long Island High Tech Incubator.
“We are excited to have the opportunity to work with the Brookhaven IDA to enable us to expand our business operation on Long Island,” said Joseph Ceccoli, President and CEO of Biocogent. “We share a strong mutual commitment to Long Island’s continued growth as a biotechnology leader in the region.”
“High-tech, well-paying manufacturing and R&D jobs like what Biocogent will bring to the Town of Brookhaven is what will help stem the brain drain of our young people,” said Frederick C. Braun III, Chairman of the Town of Brookhaven Industrial Development Agency. “The economic future of Long Island depends on attracting and retaining companies like Biocogent.”
The expansion of Biocogent’s operation will require a $10 million capital investment and additional personnel for its Bellport location. Biocogent will retain its operations and personnel currently located at the Stony Brook Long island High Technology Incubator.
BARDA DRIVe is seeking information on technologies that are relevant to AI for automated biomedical image acquisition and AI for automated biomedical image interpretation, with a focus on reducing the burden on clinical, technician, and care staff in any setting. If you can provide insight on any of the items listed below, please contact Phuong Nguyen (phuong.t.nguyen@stonybrook.edu) by June 8, 2021.
This request encompass all stages of development from early research/academic labs through start up and late commercialization: They are more interested in technical rather than any particular stage of development, thus the focus is not just on the commercial sector but also on the work being conducted at academic/research/medical/FFRDC organizations. This can be an AI solution applied to existing imaging infrastructure, or new imaging devices. This AI and imaging combination should provide new value propositions, form factors, or use cases that are only possible with integration of AI.
Specific areas and use cases of interest include but are not limited to: - Automated biomedical image interpretation, primarily in ultrasound, computer tomography, and magnetic resonance imaging. - Approaches to automated interpretation of optical and x-ray images are of interest, but of secondary priority. - AI-based diagnostic image acquisition and image interpretation in emergency medical services (EMSs) and in surgical settings to accurately assess the severity of a patient’s medical condition, e.g. the location of an internal hemorrhage or the location of a broken bone, torn ligament or other injury. - AI-based automated image reconstruction. - AI-based automated analysis of cancer screening images (e.g. mammograms) - AI-assisted image guidance for placement of medical devices, e.g. catheterization - AI-assisted fluoroscopy
[post_title] => BARDA RFI/CALL for Technologies
[post_excerpt] => BARDA DRIVe is seeking information on technologies that are relevant to AI for automated biomedical image acquisition and AI for automated biomedical image interpretation, with a focus on reducing the burden on clinical, technician, and care staff in any setting.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => barda-rfi-call-for-technologies
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-20 16:11:17
[post_modified_gmt] => 2021-09-20 16:11:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3788
[menu_order] => 43
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 5
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4906
[post_author] => 4
[post_date] => 2025-07-17 10:27:09
[post_date_gmt] => 2025-07-17 14:27:09
[post_content] =>
The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.
The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.
“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”
Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”
The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.
“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.
As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.
